Biennial report

Study Groups

Title of the study group: EULAR Antiphospholipid Syndrome (APS) Study Group

Study Group Leader’s name: prof. Maria Tektonidou
Date of annual report submission: March 20, 2020

Summary of last two years activities

EULAR recommendations for the management of Antiphospholipid Syndrome in adults
(Convenors: Maria Tektonidou/ Angela Tincani).
Members of the EULAR APS Study Group convened/ participated in a task force group from 11 European countries for the development of recommendations for the prevention and management of APS. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. The main article and the systematic literature review informing the EULAR recommendations were published in 2019 (Tektonidou MG, et al. Ann Rheum Dis. 2019;78:1296-1304; Tektonidou MG, et al. RMD Open. 2019;5(1):e000924).

EULAR Recommendations for cardiovascular management in RMDs including Systemic Lupus Erythematosus and Antiphospholipid Syndrome
(Convenors: Michael Nurmohamed/ Maria Tektonidou).
Following the EULAR standardised operating procedures, a multidisciplinary task force of experts, health professionals, EMEUNET members and patient representatives agreed upon a set of core overarching principles and recommendations for cardiovascular management of several rheumatic and musculoskeletal diseases (systemic vasculitis, Sjogren’s syndrome, systemic sclerosis, gout) including SLE and APS. The publication of the recommendations is expected in the second half of 2021.

Ongoing multicentre study including 28 centres in Europe, North and South America, and Asia-Pacific examining the prevalence and management of cardiovascular disease risk factors in patients with SLE and patients with APS (primary or SLE-related).

Collaboration between group members and other groups working on APS:

- Catastrophic APS registry project: clinical, laboratory, imaging, and histological data from cases with catastrophic APS (European Forum on Antiphospholipid Antibodies)

- Collaborative multicentre projects under the auspices of the “Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)”. Executive committee: Bertolaccini ML, Cohen H, Erkan D (Co-Chairs), Gerosa M, Andrade D, Atsumi T, Petri M, Roubey R, Tektonidou M.